PSMA4

Across TCGA pan-cancer cohorts, PSMA4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMA4 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSMA4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PSMA4 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LUAD, LSCC, and COAD are the cancer types where PSMA4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.653	0.933	.007	15	view →
LSCC	DFS	Quartile	All	1.000	0.397	.018	7	view →
COAD	DFS	Tertile	II,III,IV	0.903	1.000	.039	6	view →
HNSC	DFS	Median	IV	1.000	0.924	.037	4	view →
GBM	DFS	Median	All	0.293	0.447	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PSMA4–LUAD (OS)

Open the LUAD breakdown →